Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-10-02 00:00:00 ET · period of report 2024-09-30 · accession 0001714899-24-000200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-02 | 2024-09-30 | DNLI | Krognes Steve E. | Dir | S - Sale | $29.03 | -30.0K | 29.1K | -51% | -$870.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-30 | S | D | 30,000 | $29.03 | 29,096 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.50 to $29.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Reflects an allocation of 26,419 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person. (F4) Includes 13,467 Unvested RSUs. |